Evaluation of a bioengineered honey and Its synthetic equivalent as novel Staphylococcus aureus biofilm-targeted topical therapies in chronic rhinosinusitis
Evaluation of a bioengineered honey and Its synthetic equivalent as novel Staphylococcus aureus biofilm-targeted topical therapies in chronic rhinosinusitis
Background: chronic rhinosinusitis (CRS) is a common condition which affects the quality of life of millions of patients worldwide and has a significant impact on health-care resources. While Staphylococcus aureus bacterial biofilms play an important role in this disease, antimicrobial therapy is rarely effective and may promote antibiotic resistance. Thus, development of novel biofilm-targeting and antibiotic-sparing therapies is highly desirable and urgently required.
Objective: this in vitro study evaluated the antimicrobial activity of a novel synthetic honey-equivalent product which was designed to have the same reactive oxygen release profile as the engineered honey SurgihoneyRO™.
Methods: treatment efficacy was investigated by assessment of planktonic growth, biofilm viability, thickness, and biomass using 12 CRS-related S. aureus mucosal bacterial strains.
Results: both SurgihoneyRO™ and the synthetic honey-equivalent product inhibited growth of planktonic methicillin-resistant and methicillin-sensitive S. aureus strains, with the synthetic honey-equivalent product exhibiting a lower minimum inhibitory concentration. Treatment of established S. aureus biofilms reduced biofilm viability with 24-hour treatment resulting in a 2-log reduction in viability of biofilms formed by methicillin-resistant strains and a 1-log reduction in biofilms formed by methicillin-sensitive strains.
Conclusions: this preliminary study shows that the synthetic honey-equivalent product provides marked antimicrobial activity against S. aureus biofilms, with the potential for development in the clinical setting as an adjunctive biofilm-targeted therapy in CRS. The ultimate aim of such a product would be to reduce the need for antibiotics, steroids, and invasive surgical procedures in CRS patients as well as improving clinical outcomes following endoscopic sinus surgery.
MRSA, MSSA, Staphylococcus aureus, bacteria, bioengineered honey, biofilm, chronic rhinosinusitis, reactive oxygen species, therapy, topical
80-86
Papadopoulou, Dionyssia
435a64c4-22b0-41ff-a54e-08e41f753807
Dabrowska, Alicja
c4c5ec09-8627-4fb8-85a4-0ea2634eaa34
Harries, Philip G.
df33be64-b580-4fdf-ac4d-4c842b55d753
Webb, Jeremy
ec0a5c4e-86cc-4ae9-b390-7298f5d65f8d
Allan, Raymond
390a7d0a-38e1-410a-8dfe-c8ef8408f5e1
Salib, Rami
d6fde1c1-5b5e-43f7-ae1c-42cce6a0c9fc
1 January 2020
Papadopoulou, Dionyssia
435a64c4-22b0-41ff-a54e-08e41f753807
Dabrowska, Alicja
c4c5ec09-8627-4fb8-85a4-0ea2634eaa34
Harries, Philip G.
df33be64-b580-4fdf-ac4d-4c842b55d753
Webb, Jeremy
ec0a5c4e-86cc-4ae9-b390-7298f5d65f8d
Allan, Raymond
390a7d0a-38e1-410a-8dfe-c8ef8408f5e1
Salib, Rami
d6fde1c1-5b5e-43f7-ae1c-42cce6a0c9fc
Papadopoulou, Dionyssia, Dabrowska, Alicja, Harries, Philip G., Webb, Jeremy, Allan, Raymond and Salib, Rami
(2020)
Evaluation of a bioengineered honey and Its synthetic equivalent as novel Staphylococcus aureus biofilm-targeted topical therapies in chronic rhinosinusitis.
American Journal of Rhinology & Allergy, 34 (1), .
(doi:10.1177/1945892419874700).
Abstract
Background: chronic rhinosinusitis (CRS) is a common condition which affects the quality of life of millions of patients worldwide and has a significant impact on health-care resources. While Staphylococcus aureus bacterial biofilms play an important role in this disease, antimicrobial therapy is rarely effective and may promote antibiotic resistance. Thus, development of novel biofilm-targeting and antibiotic-sparing therapies is highly desirable and urgently required.
Objective: this in vitro study evaluated the antimicrobial activity of a novel synthetic honey-equivalent product which was designed to have the same reactive oxygen release profile as the engineered honey SurgihoneyRO™.
Methods: treatment efficacy was investigated by assessment of planktonic growth, biofilm viability, thickness, and biomass using 12 CRS-related S. aureus mucosal bacterial strains.
Results: both SurgihoneyRO™ and the synthetic honey-equivalent product inhibited growth of planktonic methicillin-resistant and methicillin-sensitive S. aureus strains, with the synthetic honey-equivalent product exhibiting a lower minimum inhibitory concentration. Treatment of established S. aureus biofilms reduced biofilm viability with 24-hour treatment resulting in a 2-log reduction in viability of biofilms formed by methicillin-resistant strains and a 1-log reduction in biofilms formed by methicillin-sensitive strains.
Conclusions: this preliminary study shows that the synthetic honey-equivalent product provides marked antimicrobial activity against S. aureus biofilms, with the potential for development in the clinical setting as an adjunctive biofilm-targeted therapy in CRS. The ultimate aim of such a product would be to reduce the need for antibiotics, steroids, and invasive surgical procedures in CRS patients as well as improving clinical outcomes following endoscopic sinus surgery.
Text
Revised Manuscript - Unmarked Version
- Accepted Manuscript
More information
Accepted/In Press date: 31 August 2019
e-pub ahead of print date: 11 September 2019
Published date: 1 January 2020
Keywords:
MRSA, MSSA, Staphylococcus aureus, bacteria, bioengineered honey, biofilm, chronic rhinosinusitis, reactive oxygen species, therapy, topical
Identifiers
Local EPrints ID: 435062
URI: http://eprints.soton.ac.uk/id/eprint/435062
ISSN: 1050-6586
PURE UUID: 11c349fd-a5ef-43ad-9058-0a7e6cd580bb
Catalogue record
Date deposited: 21 Oct 2019 16:30
Last modified: 17 Mar 2021 02:40
Export record
Altmetrics
Contributors
Author:
Dionyssia Papadopoulou
Author:
Alicja Dabrowska
Author:
Philip G. Harries
Author:
Raymond Allan
University divisions
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
